MCID: RHM027
MIFTS: 57

Rheumatic Disease

Categories: Cardiovascular diseases, Immune diseases

Aliases & Classifications for Rheumatic Disease

MalaCards integrated aliases for Rheumatic Disease:

Name: Rheumatic Disease 12 14
Rheumatic Diseases 52
Collagen Diseases 69
Rheumatism 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1575
ICD10 33 I06.9 I09.9

Summaries for Rheumatic Disease

Disease Ontology : 12 A hypersensitivity reaction type II disease that involves inflammation or pain in the muscles, joints, or fibrous tissue.

MalaCards based summary : Rheumatic Disease, also known as rheumatic diseases, is related to hepatitis b and gastric ulcer, and has symptoms including musculoskeletal symptom, myalgia and joint symptom. An important gene associated with Rheumatic Disease is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Methotrexate and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include bone, heart and eye, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and cardiovascular system

Related Diseases for Rheumatic Disease

Diseases related to Rheumatic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 378)
id Related Disease Score Top Affiliating Genes
1 hepatitis b 30.5 IFNG IL10 IL2RA TNF
2 gastric ulcer 30.1 IFNG IL10 TNF
3 atherosclerosis 29.7 HLA-DRB1 IFNG IL10 IL1B PTGS2 TNF
4 crystal arthropathies 29.7 CRP IL1R1
5 calcinosis 29.7 CD40LG CRP TNF
6 scleral disease 29.4 CD40LG IFNG IL10 IL2RA
7 myocardial infarction 29.3 CD40LG CRP IL10 IL1B PTGS2 TNF
8 pulmonary embolism 29.1 CD40LG CRP IFNG IL10 IL1B TNF
9 chronic fatigue syndrome 28.9 APOH CENPB LSM2 TRIM21
10 chickenpox 28.8 APOH CD40LG CRP HLA-B TNF VCAM1
11 rheumatoid arthritis 28.6 CD40LG CRP HLA-B HLA-DRB1 IFNG IL10
12 lymphoma 28.4 APOH CD40LG IFNG IL10 IL1B SSB
13 systemic lupus erythematosus 27.7 APOH CD40LG CRP HLA-DRB1 IFNG IL10
14 enthesopathy 11.1
15 macrophage activation syndrome 11.1
16 palindromic rheumatism 11.1
17 ramsay hunt syndrome i 10.9 HLA-B HLA-DRB1
18 migraine with brainstem aura 10.9 HLA-B HLA-DRB1 TNF
19 not otherwise specified 3-mga-uria type 10.9 HLA-B HLA-DRB1 TNF
20 epstein-barr virus hepatitis 10.9 CRP HLA-DRB1 TNF
21 aseptic meningitis 10.9 HLA-B HLA-DRB1 TNF
22 idiopathic subglottic tracheal stenosis 10.9 HLA-B HLA-DRB1 TRIM21
23 pure autonomic failure 10.9 IL10 TNF
24 spondyloarthropathy 1 10.9
25 sternal cleft 10.9 IFNG IL1B TNF
26 mosaic trisomy 1 10.9 HLA-DRB1 IFNG TNF
27 anaerobic meningitis 10.9 HLA-B HLA-DRB1 TNF
28 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.9 HLA-B IFNG TNF
29 arthus reaction 10.9 CRP IL1B TNF
30 polyarteritis nodosa 10.9 CRP IFNG TNF
31 lymphocytic colitis 10.9 HLA-DRB1 IFNG TNF
32 mazabraud syndrome 10.8 HLA-B HLA-DRB1 IFNG
33 familial mediterranean fever, ad 10.8 CRP IL1B TNF
34 amyotrophic lateral sclerosis type 10 10.8 IFNG IL1B TNF
35 acanthoma 10.8 HLA-B HLA-DRB1 IFNG
36 myeloid sarcoma 10.8 CRP IL1B TNF
37 walker dyson syndrome 10.8 IL1B IL1R1 TNF
38 brucella canis brucellosis 10.8 IL1B TNF TRIM21
39 riboflavin transporter deficiency 10.8 HLA-DRB1 TNF VCAM1
40 signet ring cell adenocarcinoma 10.8 CRP IL1R1 TNF
41 breast disease 10.8 CRP IL1B TNF
42 acute ackee fruit intoxication 10.8 IL10 TNF
43 autoimmune polyglandular syndrome type 3 10.8 IFNG TNF VCAM1
44 pulmonary plasma cell granuloma 10.8 CRP IL1B VCAM1
45 tibialis tendinitis 10.8 IL1B PTGS2 TNF
46 tabatznik syndrome 10.8 IL1B TNF
47 louping ill 10.8 CRP IFNG TNF
48 pancreas lymphoma 10.8 CRP IL1B TNF
49 autoimmune retinopathy 10.8 HLA-DRB1 IL2RA TNF
50 keloids 10.8 IL1B IL1R1 TNF

Graphical network of the top 20 diseases related to Rheumatic Disease:



Diseases related to Rheumatic Disease

Symptoms & Phenotypes for Rheumatic Disease

UMLS symptoms related to Rheumatic Disease:


musculoskeletal symptom, myalgia, joint symptom

GenomeRNAi Phenotypes related to Rheumatic Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.96 IL2RA
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.96 IL2RA
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-141 9.96 APOH
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.96 SSB
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.96 SSB IL10
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.96 IL2RA SSB APOH IL10
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.96 IL2RA
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.96 IL2RA
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 9.96 SSB
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.96 IL2RA IL10
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.96 IL10
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.96 APOH
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.96 SSB IL10
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.96 IL10
15 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 SSB TNF APOH CD40LG IL10 IL1B
16 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 SSB TNF APOH CD40LG IL10 IL1B

MGI Mouse Phenotypes related to Rheumatic Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.06 CD163 CD40LG CENPA CRP IFNG IL10
2 hematopoietic system MP:0005397 10.03 CD163 CD40LG IFNG IL10 IL1B IL1R1
3 homeostasis/metabolism MP:0005376 9.97 APOH CD163 CD40LG CRP IFNG IL10
4 immune system MP:0005387 9.77 CD163 CD40LG CRP IFNG IL10 IL1B
5 mortality/aging MP:0010768 9.47 IL1B IL1R1 IL2RA PTGS2 SSB TNF

Drugs & Therapeutics for Rheumatic Disease

Drugs for Rheumatic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 915)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
2
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 2,Phase 1 118-42-3 3652
3
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1 170277-31-3
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 83-43-2 6741
5
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 16590-41-3 5360515
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-24-8 5755
7
Sulfasalazine Approved Phase 4,Phase 3,Phase 2 599-79-1 5353980 5359476
8
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 185243-69-0
9
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
10
Leflunomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75706-12-6 3899
11
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 9004-61-9 53477741 24759
12
Milnacipran Approved Phase 4,Phase 2,Phase 3,Phase 1 92623-85-3 65833
13
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-41-2 439260
14
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2 7439-89-6 23925
15
Rivaroxaban Approved Phase 4,Phase 3 366789-02-8
16
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3,Phase 1 1197-18-8 5526
17
Tranylcypromine Approved Phase 4 155-09-9 441233
18
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2 169590-42-5 2662
19
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 1 161796-78-7, 119141-88-7 4594 9579578
20
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22204-53-1 1302 156391
21
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
22
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-02-2 5743
23
Ropivacaine Approved Phase 4,Phase 2,Phase 3 84057-95-4 71273 175805
24
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1 615258-40-7
25
Cimetidine Approved Phase 4,Phase 3,Phase 2 51481-61-9 2756
26
Hyoscyamine Approved Phase 4 101-31-5 64692
27
Etoricoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 202409-33-4 123619
28
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
29
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 331731-18-1 16219006
30
Fluorouracil Approved Phase 4 51-21-8 3385
31
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 124-94-7 31307
32
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 15307-86-5 3033
33
Abatacept Approved Phase 4,Phase 3,Phase 2,Phase 1 332348-12-6 10237
34
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
35
Amitriptyline Approved Phase 4,Phase 2,Phase 3,Phase 1 50-48-6 2160
36
Cyclobenzaprine Approved Phase 4,Phase 3,Phase 2 303-53-7 2895
37
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1 428863-50-7
38
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 51-43-4 5816
39
Ketorolac Approved Phase 4,Phase 2,Phase 3 74103-06-3, 66635-83-4 3826
40
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
41 Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1
42
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
43
Calcium Carbonate Approved Phase 4,Phase 3,Phase 2 471-34-1
44
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
45
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
46
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
47
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 27203-92-5 33741
48
Tacrolimus Approved, Investigational Phase 4,Phase 3,Early Phase 1 104987-11-3 445643 439492
49
Betamethasone Approved, Vet_approved Phase 4,Phase 3 378-44-9 9782
50
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Phase 1 15687-27-1 3672

Interventional clinical trials:

(show top 50) (show all 5826)

id Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Hanyang University Medical Center Arthritis Network Unknown status NCT00418405 Phase 4
3 Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis Unknown status NCT02087696 Phase 4 Tocilizumab
4 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
5 TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis Unknown status NCT00908089 Phase 4 Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab;Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
6 Remission Induction in Very Early Rheumatoid Arthritis Unknown status NCT00523692 Phase 4 Etanercept, methotrexate and depomedrone;depemedrone
7 Very Early Versus Delayed Etanercept in Patients With RA Unknown status NCT02433184 Phase 4 Etanercept;Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept;Methotrexate
8 Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4 Leflunomide
9 Targeting Synovitis in Early Rheumatoid Arthritis Unknown status NCT00920478 Phase 4
10 Roentgen Stereophotogrammetric Analysis (RSA) Trial Comparing Trabecular Metal Monoblock and Modular Tibial Components Unknown status NCT01180595 Phase 4
11 The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator Unknown status NCT00422643 Phase 4 Sodium hyaluronate (hyaluronic acid)
12 Validation of a Stress Device for the Knee Unknown status NCT02444663 Phase 4
13 Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4 Milnacipran;Placebo
14 Intravenous Iron Sucrose in Arthroplasty Unknown status NCT02544828 Phase 4 Iron Sucrose 200mg;placebo
15 The Post-marketing Surveillance to Evaluate the Efficacy of CHONDRON (Autologous Cultured Chondrocyte) by Arthroscopy Unknown status NCT02539069 Phase 4
16 The Post-marketing Surveillance to Evaluate the Efficacy and Safety of a CHONDRON (Autologous Cultured Chondrocyte) Unknown status NCT02539056 Phase 4
17 Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
18 Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty Unknown status NCT02453802 Phase 4 Tranexamic Acid 5%,5ml/amp;Tranexamic Acid 5%,5ml/amp;rivaroxaban (10mg);0.9% Normal Saline;0.9% Normal Saline
19 Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
20 Medical Chitosan or Sodium Hyaluronate for Knee Osteoarthritis (CHOOSE) Unknown status NCT02323451 Phase 4 Sodium Hyaluronate Injection
21 Tranexamic Acid in Knee Joint Surgery Unknown status NCT02278263 Phase 4 Tranexamic Acid;Normal saline (0.9% NaCl)
22 Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty Unknown status NCT02152917 Phase 4 Tranexamic acid;Floseal®
23 Intraarticular Xylitol Injections for Knee Osteoarthritis Unknown status NCT02104596 Phase 4
24 The Effect of Spironolactone on Pain in Older People With Osteoarthritis Unknown status NCT02046668 Phase 4 spironolactone
25 Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy Unknown status NCT02000297 Phase 4
26 A Phase 4 Study of Imrecoxib in Treatment of Knee Osteoarthritis Unknown status NCT01985165 Phase 4 Imrecoxib
27 Comparison of Femoral Nerve Catheter and Adductor Canal Block With Steroid Adjuvant in Total Knee Replacement (TKR) Unknown status NCT01973530 Phase 4
28 Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women Unknown status NCT01926158 Phase 4 Denosumb;Placebo (for denosumab)
29 Reinflation After Early Tourniquet Release in Total Knee Arthroplasty Unknown status NCT01832272 Phase 4
30 Hip Viscosupplementation: What is the Best Dosage? Unknown status NCT01810809 Phase 4 1 ampoule of Hylan GF-20;2 ampoules of Hylan GF-20;3 ampoules of Hylan GF-20
31 Bone Forming at Prosthetic Surfaces. Fingerprint2 Unknown status NCT01623687 Phase 4
32 RSA Study Using Two Types of Uncemented Acetabular Components and the Uncemented HA Coated Symax Stem Unknown status NCT01618084 Phase 4
33 Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis. Unknown status NCT01233739 Phase 4 Chondroitin sulfate;Placebo
34 Assessment of the Effects of Chondroitin Sulphate in Patients With Knee Osteoarthritis With Functional Magnetic Resonance Imaging (fMRI) Unknown status NCT01226615 Phase 4 Chondroitin sulphate (Condrosan®);Placebo
35 Comparison of Outcomes in Mobile and Fixed-bearing Total Knee Arthroplasty Unknown status NCT01027819 Phase 4
36 The Impact of Hyaluronic Acid Injections on Osteoarthritic Knee Mechanics Unknown status NCT00778076 Phase 4
37 Use of Cold and Compression Therapy With Total Knee Replacement Patients Unknown status NCT00712816 Phase 4
38 Trial Comparing Navigated and Conventional Implantation Techniques in Knee Replacement Surgery Unknown status NCT00431509 Phase 4
39 Effectiveness Study of Hylan G-F 20 to Preserve Cartilage in Osteoarthritis of the Knee Unknown status NCT00393393 Phase 4 intra-articular injection of Hylan G-F 20
40 Effect of Flex-a-New on Osteoarthritis of the Knee Unknown status NCT00294801 Phase 4 flex-a-new (food supplement)
41 Comparing Clinical Outcome of 2 Different Total Knee Prostheses: Nexgen LPS-Flex Versus AGC Unknown status NCT00294528 Phase 4
42 Efficacy of Celecoxib Vs Placebo to Prevent Pain in a Paced Walk Unknown status NCT00194090 Phase 4 celecoxib
43 Hyaluronan Versus NaCl 20 Ml Versus Placebo in Knee Osteoarthritis Unknown status NCT00144820 Phase 4 Injection of Hyaluronan or Saline
44 A Randomized Controlled Trial of Long Versus Short Wait For Primary Total Hip and Knee Arthroplasty Unknown status NCT00138892 Phase 4
45 Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia Unknown status NCT00755521 Phase 4 etoricoxib
46 Study of Fibromyalgia Treated With Milnacipran Unknown status NCT01125423 Phase 4 Milnacipran
47 Bipolar Sealer Aquamantys Use in Total Knee Replacement Unknown status NCT01736644 Phase 4
48 Comparison Between Anterior and Direct Lateral Approach in Total Hip Arthroplasty Unknown status NCT01578746 Phase 4
49 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
50 Danish Multicenter Study of Adalimumab in Spondyloarthritis Unknown status NCT00477893 Phase 4 Adalimumab;Placebo

Search NIH Clinical Center for Rheumatic Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Rheumatic Disease

Anatomical Context for Rheumatic Disease

MalaCards organs/tissues related to Rheumatic Disease:

39
Bone, Heart, Eye, Testes, Bone Marrow, Brain, Skin

Publications for Rheumatic Disease

Articles related to Rheumatic Disease:

(show top 50) (show all 879)
id Title Authors Year
1
Total Chordal Sparing Mitral Valve Replacement in Rheumatic Disease: A Word of Caution. ( 28633260 )
2017
2
Ehlers-Danlos syndrome hypermobility type is associated with rheumatic diseases. ( 28051109 )
2017
3
Neurological Complications of Rheumatic Disease. ( 28779866 )
2017
4
Post-Chikungunya Rheumatic Disease in a 13-Year-Old Boy. ( 28884916 )
2017
5
Mortality causes and outcomes in Indigenous populations of Canada, the United States, and Australia with rheumatic disease: A systematic review. ( 28823732 )
2017
6
Re: Re: Did King Herod suffer from a rheumatic disease? doi: 10.1007/s10067-017-3583-z. ( 28733793 )
2017
7
Association between demyelinating disease and autoimmune rheumatic disease in a pediatric population. ( 28535894 )
2017
8
Development, Sensibility, and Validity of a Systemic Autoimmune Rheumatic Disease Case Ascertainment Tool. ( 27803141 )
2017
9
Paediatric rheumatic disease: What is the best definition of clinical remission in JIA? ( 28660911 )
2017
10
Re: Did King Herod suffer from a rheumatic disease? doi: 10.1007/s10067-017-3583-z. ( 28733792 )
2017
11
Causes and consequences of endoplasmic reticulum stress in rheumatic disease. ( 27904144 )
2017
12
Sexual and reproductive health in rheumatic disease. ( 28680137 )
2017
13
Simple screening tools predict death and cardiovascular events in patients with rheumatic disease. ( 28812405 )
2017
14
Systematic review and meta-analysis of the epidemiology of polyautoimmunity in SjAPgren's syndrome (secondary SjAPgren's syndrome) focusing on autoimmune rheumatic diseases. ( 28927315 )
2017
15
Paediatric rheumatic disease: Systemic JIA genetically distinct. ( 28077866 )
2017
16
Heterotopic ossification (myositis ossificans progressiva): A condition interfering with rheumatic disease. ( 28293462 )
2017
17
The signaling adaptor TRAF1 negatively regulates Toll-like receptor signaling and this underlies its role in rheumatic disease. ( 27893701 )
2017
18
Fatigue and psychosocial variables in autoimmune rheumatic disease and chronic fatigue syndrome: A cross-sectional comparison. ( 27998507 )
2017
19
Adaptation to inflammatory rheumatic disease: Do illness representations predict patients' physical functioning over time? A complex relationship. ( 28936564 )
2017
20
Paediatric rheumatic disease: What is the best definition of clinical remission in JIA? ( 28725036 )
2017
21
Robot-Assisted Mitral Valve Repair With Posterior Leaflet Extension for Rheumatic Disease. ( 28085691 )
2017
22
Filling the gaps in SARDs research: collection and linkage of administrative health data and self-reported survey data for a general population-based cohort of individuals with and without diagnoses of systemic autoimmune rheumatic disease (SARDs) from British Columbia, Canada. ( 28637725 )
2017
23
Therapy: Rheumatic disease after immune checkpoint inhibitor therapy. ( 28660915 )
2017
24
The Incidence of Atypical Femoral Fractures in Patients with Rheumatic Disease: Yamagata Prefectural Committee of Atypical Femoral Fractures (YamaCAFe) Study. ( 28883214 )
2017
25
Clinical characteristics of autoimmune rheumatic disease-related organizing pneumonia. ( 28748510 )
2017
26
Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study. ( 28535619 )
2017
27
Rare Cyclophosphamide-Induced Hemorrhagic Cystitis in a Chinese Population with Rheumatic Diseases. ( 28646351 )
2017
28
Population Genetics and Natural Selection in Rheumatic Disease. ( 28711136 )
2017
29
Clinical Value of FDG-PET/CT for the Evaluation of Rheumatic Diseases: Rheumatoid Arthritis, Polymyalgia Rheumatica, and Relapsing Polychondritis. ( 28583280 )
2017
30
What do young people with rheumatic disease believe to be important to research about their condition? A UK-wide study. ( 28673355 )
2017
31
Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease. ( 28711176 )
2017
32
Macrophage Activation Syndrome in Paediatric Rheumatic Diseases. ( 28588173 )
2017
33
The complement system as a potential therapeutic target in rheumatic disease. ( 28794515 )
2017
34
Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry. ( 28737837 )
2016
35
Prevalence and the clinical outcome of atrial fibrillation in patients with Autoimmune Rheumatic Disease. ( 27055157 )
2016
36
Usefulness of two interferon-I^ release assays for rheumatic disease. ( 26670306 )
2016
37
Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis. ( 27924645 )
2016
38
Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). ( 26746234 )
2016
39
The Role of Autophagy in Rheumatic Disease. ( 27550202 )
2016
40
Implications of Rheumatic Disease and Biological Response-Modifying Agents in Plastic Surgery. ( 27002562 )
2016
41
CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases. ( 27216429 )
2016
42
The microbiota in pediatric rheumatic disease: epiphenomenon or therapeutic target? ( 27286235 )
2016
43
Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: A case-control study. ( 27814896 )
2016
44
Autoimmune vitiligo in rheumatic disease in the mestizo Mexican population. ( 27446537 )
2016
45
Management of Chronic Post-Chikungunya Rheumatic Disease: The Martinican Experience. ( 27273928 )
2016
46
Association between Air Pollution and the Development of Rheumatic Disease: A Systematic Review. ( 27847517 )
2016
47
Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. ( 26780533 )
2016
48
Fine particulate air pollution and systemic autoimmune rheumatic disease in two Canadian provinces. ( 26724462 )
2016
49
TNF inhibitors increase fat mass in inflammatory rheumatic disease: a systematic review with meta-analysis. ( 27974099 )
2016
50
Rheumatic Disease Autoantibodies in Autoimmune Liver Diseases. ( 27409579 )
2016

Variations for Rheumatic Disease

Expression for Rheumatic Disease

Search GEO for disease gene expression data for Rheumatic Disease.

Pathways for Rheumatic Disease

Pathways related to Rheumatic Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 CD40LG CRP HLA-B HLA-DRB1 IFNG IL10
2
Show member pathways
13.21 CD40LG HLA-B HLA-DRB1 IFNG IL10 IL1B
3
Show member pathways
12.87 CD40LG HLA-B HLA-DRB1 IFNG IL10 IL1B
4
Show member pathways
12.85 HLA-B HLA-DRB1 IFNG IL1B IL2RA TNF
5
Show member pathways
12.71 CD40LG IFNG IL1B IL1R1 TNF
6
Show member pathways
12.68 CD40LG HLA-DRB1 IFNG IL10 IL2RA TNF
7
Show member pathways
12.63 HLA-DRB1 IFNG IL10 IL1B IL1R1 IL2RA
8
Show member pathways
12.58 HLA-B HLA-DRB1 IFNG TRIM21 VCAM1
9 12.5 HLA-B HLA-DRB1 IL1R1 IL2RA TNF VCAM1
10
Show member pathways
12.49 CD40LG IFNG IL10 IL1B TNF
11 12.47 CD40LG IFNG IL10 IL1B IL2RA PTGS2
12
Show member pathways
12.36 IFNG IL1B PTGS2 TNF
13 12.33 HLA-B HLA-DRB1 IFNG IL10
14
Show member pathways
12.32 IFNG IL1B IL1R1 PTGS2 TNF
15 12.29 HLA-DRB1 IFNG IL10 IL1B TNF
16
Show member pathways
12.25 CD40LG HLA-DRB1 IFNG IL10 IL1B PTGS2
17
Show member pathways
12.23 IFNG IL1B IL1R1 TNF
18
Show member pathways
12.22 HLA-B IFNG IL10 IL1B TNF
19 12.16 CD40LG HLA-B HLA-DRB1 VCAM1
20 12.16 IFNG IL1B IL1R1 TNF VCAM1
21 12.1 IFNG IL1B IL1R1 TNF
22 12.08 IFNG IL1B IL1R1 PTGS2 TNF
23 12.06 CD163 IFNG IL10 IL2RA TNF
24 12.05 IL10 IL1B PTGS2 TNF VCAM1
25
Show member pathways
12.03 HLA-DRB1 IFNG IL1B IL1R1 IL2RA
26